Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

ions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implementation of ChemoCentryx's business model, strategic plans for its business, product candidates and technology, (vi) ChemoCentryx's ability to maintain and establish collaborations or obtain additional government grant funding, (vii) ChemoCentryx's estimates of its expenses, future revenues, capital requirements and its needs for additional financing, (viii) the timing or likelihood of regulatory filings and approvals, (ix) the availability of corporate partners, (x) the scope of protection ChemoCentryx is able to establish and maintain for intellectual property rights covering its product candidates and technology, (xi) the impact of competitive products and technological changes, (xii) the availability of capital and the cost of capital, (xiii) ChemoCentryx's financial performance, (xiv) developments relating to ChemoCentryx's competitors and other vagaries in the biotechnology industry and (xv) other risks.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and ChemoCentryx undertakes no obligation to revise or update this press release to reflect event
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... One of the major trends in the market ... useful in different application sectors such as hard tissue ... forecast the Global Bioactive Material Market to ... period 2013-2018. According to the report, increase in aging ... market. There will be an increased number of trauma, ...
(Date:9/19/2014)... Mount Pleasant Retirement Village has partnered ... Well-Being Coach Christi Hall to campus. , Hall’s journey to ... and gaining weight as a result of years of medication. ... about nutrition. One year later she had lost 50 pounds, ... endurance and cardio. , After joining the YMCA staff, she ...
(Date:9/19/2014)... There are thousands of older women who ... and there are thousands of younger men who would love ... SeekingCougar.com now provides the world's best collection of resources ... older women, and the younger men who would like to ... these people to meet each other and establish those romantic ...
(Date:9/18/2014)... Thompson and Mathieu Nikel decided it was time to tie the ... Isaac, said there was only one choice for them – Mercy ... Thompson was an undergraduate student and needed a French tutor. She ... French and so she asked him. , Thompson is ... was 7 years old. Nikel is originally from France came ...
(Date:9/18/2014)... Dr. David A. F. Ellis is a ... of Facial Plastic and Reconstructive Surgery and a Professor ... Facial Plastic Surgery. He is recognized around the ... , Dr. Ellis will be presenting on numerous injectable ... injection techniques and various treatments for complications associated with ...
Breaking Medicine News(10 mins):Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 2Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 3Health News:Bioactive Material Market to Grow at 13.30% CAGR to 2018, Forecasts a New Research Report Available at Sandlerresearch.org 4Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 2Health News:Mount Pleasant Retirement Village Partners with Atrium Family YMCA 3Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2
... Oct. 17 Symmetry Medical Inc.,(NYSE: SMA ... global orthopedic,device industry and other medical markets, announced ... Officer, Europe effective November 1,2007. Mr. Hynes ... case facilities across Europe including the UK, Ireland,France ...
... against the facial paralysis, study finds , , WEDNESDAY, Oct. 17 ... at easing a form of facial paralysis called Bell,s palsy ... that acyclovir may not be a new, improved treatment option ... the other hand, many people afflicted with Bell,s palsy do ...
... receive failing grades , , WEDNESDAY, Oct. 17 (HealthDay News) -- ... to women,s health, a new report contends. , The report ... meets only three of 27 benchmarks for women,s health. Those ... who get regular mammograms; the percentage of women who visit ...
... Include New Research on HIV Screening, Pandemic Flu,Neonatal ... WASHINGTON, Oct. 17 More than 13,000 public,health ... to address the,nation,s top public health challenges at ... The conference will feature leading experts, researchers ...
... Oct. 17 Two health care leaders were,presented ... (MHA),Health Care Leadership Award. Terence F. Moore, president ... the award in the,category of hospital management and ... with the award in the category of patient ...
... Lumenos suite of products helps consumers manage costs and adopt healthier ... ... Anthem Blue Cross and Blue,Shield in Virginia is now offering new health ... about health,care-helping them to lead healthier lives and gain control over the ...
Cached Medicine News:Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 2Health News:Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe 3Health News:Antiviral Won't Improve Bell's Palsy Outcome 2Health News:U.S. Women's Health Care Still Falls Short: Report 2Health News:U.S. Women's Health Care Still Falls Short: Report 3Health News:Thousands of Public Health Experts to Address Leading Issues at APHA Annual Meeting, Nov. 3-7 2Health News:Association Honors Health Care Leaders in Midland and Troy 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 2Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 3Health News:Anthem Blue Cross and Blue Shield in Virginia Introduces New Generation of Consumer Driven Health Products 4
... The Infinity AST (GOT) powder reagent ... convenience of single liquid stability to help ... provide quick result turnaround time. The patented ... reagent provides a long shelf life and ...
LCD chart display...
... are extremely delicate and if repairs are ... can easily be damaged beyond repair and ... , On the other hand, with conscientious ... have a virtually indefinite lifespan. The very ...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: